PEG-MGF (Pegylated Mechano Growth Factor) — Research Overview
Full Name: Pegylated Mechano Growth Factor Abbreviation: PEG-MGF Also Known As: PEG-IGF-1Ec, PEGylated MGF, pegylated myotrophin Core Peptide Sequence (MGF E-domain): 24-amino acid synthetic peptide corresponding to the C-terminal E-domain of the IGF-1Ec splice variant. Sequence: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys (with PEG attachment typically via succinyl linkage) PEGylation: Polyethylene glycol (PEG) is covalently attached to the MGF peptide — typically via a succinyl linker — dramatically increasing the peptide’s molecular hydrodynamic radius, conferring resistance to enzymatic degradation, and extending in vivo biological activity from the native MGF’s short action window to an estimated 48-72 hours. Parent Molecule: Mechano Growth Factor (MGF, also designated IGF-1Ec in humans and IGF-1Eb in rodents) — a splice variant of the Insulin-like Growth Factor-1 gene produced locally in skeletal muscle, cardiac muscle, bone, and neural tissue in response to mechanical strain, damage, or ischemia. Molecular Formula (core peptide): C121H200N42O39 Regulatory Status: Not FDA-approved for any indication. No approved regulatory status in any major jurisdiction. WADA prohibited under S2. WADA Status: Prohibited under S2 (peptide hormones, growth factors, related substances, and mimetics) Category: IGF-1 gene splice variant analog / satellite cell activator / local anabolic signaling tool / tissue repair research peptide / muscle regeneration research compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is PEG-MGF?
PEG-MGF is a pegylated synthetic analog of Mechano Growth Factor — an endogenous splice variant of the IGF-1 gene that is produced locally in mechanically stressed, damaged, or ischemic tissue. To understand PEG-MGF, its parent biology must be understood first.
The IGF-1 gene undergoes complex tissue-specific alternative splicing that produces several distinct isoforms with different functional profiles. The most abundant systemic form, IGF-1Ea, is produced predominantly by the liver under growth hormone stimulation and circulates as an endocrine signal promoting systemic anabolic effects. A distinct splice variant — IGF-1Ec in humans (designated IGF-1Eb in rodents) — was discovered in stretched and electrically stimulated rabbit skeletal muscle in the mid-1990s by the laboratory of Geoffrey Goldspink at the Royal Free and University College Medical School in London. Because this isoform was expressed in response to mechanical stimulation rather than endocrine signaling, Goldspink named it Mechano Growth Factor.
MGF’s biological distinctiveness derives from a 49-base pair insert in exon 5 (52 base pairs in rodents) that shifts the reading frame and produces a unique C-terminal E-domain sequence absent from IGF-1Ea. This E-domain gives MGF a fundamentally different biological activity profile from systemic IGF-1. While IGF-1Ea primarily promotes myoblast differentiation and sustained anabolic growth, MGF promotes satellite cell activation and myoblast proliferation — the earlier stages of muscle repair. These are temporally distinct processes: MGF is expressed in a pulse-like fashion in the first 24 to 48 hours after muscle damage, preceding and enabling the longer-duration IGF-1Ea expression that follows. The two splice variants together coordinate a sequential repair cascade: MGF launches the satellite cell proliferative response, IGF-1Ea sustains differentiation and growth.
The synthetic MGF research tool used in most studies — and from which PEG-MGF is derived — is the 24-amino acid C-terminal peptide of the IGF-1Ec E-domain (MGF-24aa). This peptide has been shown in multiple in vitro and in vivo studies to activate satellite cells, promote myoblast proliferation, delay premature differentiation, and protect against apoptosis. PEG-MGF adds polyethylene glycol conjugation to this core sequence, dramatically extending its stability and providing a pharmacokinetic profile suitable for sustained experimental protocols rather than the rapid clearance of the native MGF peptide.
The IGF-1 Splicing Cascade and MGF’s Position Within It
The relationship between MGF and conventional IGF-1 is central to understanding what PEG-MGF is and is not as a research compound.
All IGF-1 isoforms share an identical mature IGF-1 domain — the 70-amino acid region encoded by exons 3 and 4 that contains the receptor-binding sequence for the IGF-1 receptor (IGF-1R). What distinguishes isoforms is the C-terminal extension (the E-domain) encoded by variable exon combinations. IGF-1Ea has the Ea extension; MGF (IGF-1Ec/Eb) has the distinct E-domain with the frameshifted insert.
In the MGF hypothesis developed by Goldspink and colleagues, after muscle injury or mechanical overload the IGF-1 gene is first spliced preferentially toward the Eb/Ec (MGF) variant, producing a burst of local MGF expression lasting approximately 24 hours. During this early phase, MGF E-domain peptide activates quiescent satellite cells, driving them into the cell cycle and promoting myoblast proliferation. Critically, MGF simultaneously inhibits myoblast differentiation — keeping the proliferating pool expanding rather than prematurely differentiating into post-mitotic fibers. As MGF levels decline, the Igf1 gene increasingly splices toward IGF-1Ea production, which promotes myoblast differentiation, myotube formation, and sustained muscle fiber repair and hypertrophy. The two splice variants thus function as a temporal relay — MGF amplifies the stem cell pool, IGF-1Ea drives their differentiation into mature fibers.
A critical mechanistic consideration: the synthetic 24-amino acid MGF E-domain peptide used in research appears to signal through a mechanism at least partially independent of the canonical IGF-1 receptor. Where IGF-1R activation drives the PI3K/Akt pathway (strongly anabolic and anti-apoptotic) and MAPK/ERK pathway, the MGF E-domain peptide has been reported to activate ERK but not Akt — suggesting a distinct receptor or signaling mechanism. A specific MGF receptor has not been conclusively identified, and the mechanism by which the E-domain exerts its satellite cell activating and neuroprotective effects is an active research question. This mechanistic ambiguity is an important honest limitation to acknowledge.
PEGylation — Why It Matters
The native MGF peptide has a severely limited in vivo half-life due to rapid enzymatic degradation in blood and tissue. This rapid clearance restricts its utility in research protocols requiring sustained pathway activation. PEGylation — the covalent attachment of polyethylene glycol — addresses this limitation through two primary mechanisms.
Physical shielding: The large hydrophilic PEG polymer creates a steric shield around the peptide backbone, physically blocking access by proteases and other degrading enzymes. This dramatically reduces the rate of enzymatic cleavage.
Increased hydrodynamic radius: The PEG chain dramatically increases the effective molecular size of the conjugate, reducing kidney filtration and renal clearance — a primary route by which small peptides are eliminated from circulation.
The net result is that PEG-MGF maintains biological activity over an estimated 48 to 72 hours compared to the much shorter activity window of non-pegylated MGF — enabling experimental designs that require sustained MGF receptor engagement or systemic distribution, which would be impossible with the rapidly cleared native peptide.
Mechanism of Action
Satellite cell activation and myoblast proliferation: The primary and best-characterized action of the MGF E-domain peptide is activation of quiescent muscle satellite cells — the resident muscle stem cells that are the source of all regenerative myoblasts following muscle injury or atrophy. Under resting conditions, satellite cells remain quiescent beneath the basal lamina of muscle fibers. Following mechanical damage or stretch, MGF expression in the muscle fiber provides the local paracrine signal that drives satellite cells to exit quiescence, enter the cell cycle, and begin dividing as myoblasts. MGF E-peptide promotes this proliferative expansion while simultaneously inhibiting premature terminal differentiation — keeping the myoblast pool dividing and expanding before committing to fiber formation.
Distinction from IGF-1 receptor-mediated growth: The mature IGF-1 domain common to all IGF-1 isoforms activates IGF-1R and drives PI3K/Akt (anabolic, anti-apoptotic) signaling. The E-domain of MGF — the pharmacologically active sequence in PEG-MGF — appears to act through a distinct pathway, primarily activating ERK rather than Akt signaling. This mechanistic distinction may explain why MGF E-peptide primarily promotes proliferation (an ERK-associated effect) while IGF-1Ea more strongly promotes differentiation (an Akt/mTOR-associated effect). Importantly, one systematic study by Fornaro et al. failed to reproduce satellite cell proliferative effects of the MGF E-peptide at concentrations up to 500 ng/ml in C2C12 cells and primary human myoblasts — while full-length IGF-1Eb and mature IGF-1 did show proliferative effects. This negative finding is a significant honest limitation of the MGF E-peptide research and must be acknowledged.
Neuroprotection through Nrf2/heme oxygenase-1: The MGF E-domain peptide has demonstrated neuroprotective effects in multiple model systems. In neuronal cell culture, MGF-24aa protected SH-SY5Y neurons from neurotoxin-induced apoptosis through a mechanism involving PKC-mediated activation of Nrf2 (NF-E2-related factor-2), which increases expression of heme oxygenase-1 (HO-1). HO-1 is a potent cytoprotective enzyme that degrades pro-oxidant heme, produces carbon monoxide (with vasodilatory and anti-inflammatory effects), and generates biliverdin/bilirubin (antioxidants). In vivo, MGF infusion into rat substantia nigra protected dopaminergic neurons from neurotoxin-induced cell death and motor behavior deficits in a Parkinson’s disease model. A strong neuroprotective effect of the autonomous C-terminal MGF peptide was also documented in brain ischemia.
Cardiac protection following myocardial infarction: MGF expression is upregulated in cardiac muscle following ischemia, and studies in sheep demonstrated that treatment with MGF E-domain peptide reduced the area of at-risk myocardium and preserved cardiac function after experimentally induced myocardial infarction — with effects comparable to or better than mature IGF-1 at the same doses. The mechanism is thought to involve cardiomyocyte protection from ischemia-induced apoptosis, possibly through the same HO-1/Nrf2 neuroprotective pathway active in neurons.
Age-related decline in MGF expression — sarcopenia relevance: A critical translational observation is that MGF expression in response to mechanical overload or exercise declines substantially with age. In both rodents and humans, older muscle shows a blunted MGF response to resistance exercise and mechanical stimulation compared to young muscle — a deficit that may contribute to the impaired satellite cell activation and progressive loss of regenerative capacity that underlies age-related sarcopenia. This observation has driven research interest in MGF or PEG-MGF as a potential tool to restore the satellite cell activation signal that aging muscle fails to generate adequately.
Neurogenesis in the aging brain: MGF expression was found in neurogenic regions of the mouse brain (dentate gyrus and subventricular zone) and this expression declined with age. Transgenic overexpression of MGF in mice significantly increased BrdU-positive proliferative cells in the hippocampal dentate gyrus — documenting a role for MGF in adult hippocampal neurogenesis analogous to its satellite cell activation function in skeletal muscle.
Published Research
Study 1 — Original Discovery: Cloning and Characterization of MGF in Mechanically Stimulated Muscle
Authors: Yang SY, Alnaqeeb M, Simpson H, Goldspink G (Royal Free and University College Medical School, London) Year: 1996 Journal: Journal of Muscle Research and Cell Motility Full text referenced via: J Muscle Res Cell Motil. 1996;17(4):487-495
This foundational paper reported the original identification and cloning of what would be named Mechano Growth Factor — the first documentation that the IGF-1 gene produces a distinct splice variant specifically in mechanically stimulated skeletal muscle.
The IGF-1 gene in rabbit skeletal muscle subjected to stretch and electrical stimulation expressed a novel RNA transcript containing a 52-base pair insert in rodents (49 bp in humans) that shifted the reading frame to generate a unique C-terminal E-domain sequence.
This novel isoform was expressed specifically in response to mechanical stimulation — not in unstimulated contralateral control muscles — establishing the mechanical induction specificity that prompted the name Mechano Growth Factor.
The discovery established that the IGF-1 gene has tissue-specific and stimulus-specific splicing programs, and that the product of these programs is not merely a variant delivery mechanism for mature IGF-1 but a peptide with a distinct C-terminal sequence with independent biological potential.
Study 2 — MGF E-Domain and Myoblast Proliferation vs Differentiation: Differential Roles
Authors: Yang SY, Goldspink G (Royal Free and University College Medical School) Year: 2002 Journal: FEBS Letters Referenced via: FEBS Lett. 2002;522(1-3):156-160
This study directly compared the biological activities of the MGF E-domain peptide and mature IGF-1 in myoblasts, establishing the division of labor between the two IGF-1-derived factors in muscle repair.
The MGF-24aa E-domain peptide promoted myoblast proliferation and delayed terminal differentiation, while mature IGF-1 promoted differentiation — directly establishing the temporal and functional relay model by which the two splice variant products coordinate muscle repair.
The temporal ordering has direct mechanistic significance: MGF must act first to amplify the satellite cell pool, but its differentiation-inhibiting activity means that it must be cleared before the differentiation phase can proceed. This temporal constraint explains why MGF is expressed in a short pulse after muscle damage while IGF-1Ea expression follows for longer.
This study’s finding that MGF E-peptide promotes proliferation while inhibiting differentiation was foundational for all subsequent research and positioned MGF-based therapeutics as satellite cell activators rather than direct growth-promoting agents — a biologically more nuanced and mechanistically specific classification.
Study 3 — Human Clinical Observation: MGF Expression Declines With Age After Resistance Exercise
Authors: Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SDR Year: 2003 Journal: Journal of Physiology Full text referenced via: J Physiol. 2003;547(Pt 1):247-254. PMID: 12562970
This study directly measured IGF-1 splice variant expression in young and old human skeletal muscle biopsies before and after high-resistance exercise — the first direct human evidence for age-related impairment of MGF expression.
Muscle biopsies were obtained from young (mean age 24 years) and old (mean age 70 years) healthy male volunteers before and after a single bout of high-resistance exercise. RT-PCR analysis quantified relative expression of IGF-1Ea and MGF (IGF-1Ec) splice variants.
In young subjects, resistance exercise produced a significant increase in MGF expression in skeletal muscle. In old subjects, this MGF response to exercise was substantially blunted — establishing that aged muscle loses the ability to adequately upregulate the local satellite cell activation signal in response to mechanical challenge.
IGF-1Ea expression did not show the same age-related impairment — suggesting that the deficit is specifically in the mechanically sensitive MGF splicing program rather than in IGF-1 expression generally.
These human data directly supported the hypothesis that impaired MGF expression contributes to the reduced satellite cell activation capacity and progressive muscle mass loss of aging, and provided a clinical rationale for exploring MGF supplementation as a potential strategy to restore the blunted repair signal in aged muscle.
Study 4 — MGF E-Peptide Activates Human Satellite Cells Across Age Groups With Sarcopenia Implications
Authors: Kandalla PK, Goldspink G, Butler-Browne G, Mouly V (Institut de Myologie, Paris) Year: 2011 Journal: Mechanisms of Ageing and Development PMID: 21354439 Full text: https://pubmed.ncbi.nlm.nih.gov/21354439/
This study examined the direct effects of the MGF-24aa E-peptide on primary human satellite cells isolated from donors of different ages — neonatal, young adult, and old adult — providing the most directly relevant human cell-based evidence for MGF E-peptide activity.
MGF-E peptide significantly increased the proliferative life span of satellite cells from neonatal and young adult donors, delaying cellular senescence and extending the period of productive proliferation. Old adult satellite cells showed this response to a lesser degree, suggesting that the responsiveness of satellite cells themselves also declines with age.
Hypertrophy was induced in all cultures, associated with decreased reserve cell percentages — consistent with satellite cell commitment to the myogenic program.
The authors concluded that the MGF-24aa-E peptide alone has a marked ability to enhance satellite cell activation, proliferation, and fusion for muscle repair and maintenance — and specifically highlighted its potential as a strategy to combat age-related sarcopenia without the oncogenic side effects associated with systemic IGF-1 supplementation. This sarcopenia-without-IGF-oncogenesis framing is a significant pharmacological distinction: while systemic IGF-1 at therapeutic doses raises concerns about stimulating pre-existing tumor growth through IGF-1R on cancer cells, the E-domain peptide’s potentially distinct signaling mechanism may avoid some of these concerns — though this distinction requires further mechanistic validation.
Study 5 — Cardiac Protection: MGF Reduces Loss of Cardiac Function After Myocardial Infarction
Authors: Carpenter V, Matthews K, Devlin G et al. (Waikato Hospital, New Zealand) Year: 2008 Journal: Heart, Lung and Circulation Full text referenced via: Heart Lung Circ. 2008;17(1):33-39
This sheep model study evaluated whether MGF treatment could reduce myocardial damage and preserve cardiac function after experimentally induced acute myocardial infarction — extending MGF research beyond skeletal muscle to the cardiac application suggested by its upregulation after cardiac ischemia.
Infarcts were induced in sheep by microsphere injection. Animals received vehicle, mature IGF-1, MGF E-domain peptide, or full-length MGF at 200 nM doses. Cardiac function was assessed by echocardiography at 8 days post-infarction.
MGF E-domain treatment reduced the area of at-risk myocardium and improved post-infarct cardiac function — with effects at least comparable to mature IGF-1 in the same model.
The finding that MGF is upregulated in the heart and brain following ischemia — parallel to its upregulation in skeletal muscle following mechanical damage — suggests a general role for MGF as an acute-phase local repair and cytoprotection signal across multiple tissue types, not merely in skeletal muscle.
Study 6 — Neuroprotection and Neurogenesis: MGF in the Aging Brain
Authors: Tang JJ, Podratz JL, Lange M et al. Year: 2017 Journal: Molecular Brain Full text: https://link.springer.com/article/10.1186/s13041-017-0304-0
This study documented endogenous MGF expression in neurogenic regions of the aging mouse brain and characterized the effects of MGF overexpression on adult hippocampal neurogenesis — extending the biological reach of MGF from muscle to the CNS.
Endogenous MGF was expressed in the dentate gyrus (DG) of the hippocampus and subventricular zone (SVZ) of control mice, and these levels declined with age — mirroring the age-related decline in skeletal muscle MGF expression.
Transgenic overexpression of MGF significantly increased BrdU-positive proliferative cells in both the hippocampal dentate gyrus and subventricular zone, confirming that MGF promotes neural progenitor cell proliferation in neurogenic regions of the adult brain.
The mechanistic parallel between MGF’s satellite cell-activating role in skeletal muscle and its neural progenitor-activating role in the hippocampus suggests a conserved function in activating tissue-specific stem cell pools in response to stress or damage — a potentially important concept for understanding the breadth of MGF’s biological significance.
Important Research Limitations and Mechanistic Controversies
The MGF E-domain peptide research has an honest controversy that must be acknowledged in any rigorous scientific overview. A 2014 study by Fornaro et al. published in the American Journal of Physiology (Endocrinology and Metabolism) directly attempted to reproduce the claimed proliferative effects of MGF peptide on human and mouse muscle myoblasts in vitro. Concentrations of synthetic MGF E-peptide up to 500 ng/ml failed to increase proliferation of C2C12 cells or primary human skeletal muscle myoblasts in either study laboratory — despite full-length IGF-1Eb and mature IGF-1 producing clear proliferative responses at the same concentrations.
This is a significant negative result. It raises the possibility that the satellite cell proliferative effects attributed to synthetic MGF E-peptide in some studies may reflect experimental conditions, peptide preparation issues, or cell line-specific artifacts rather than a universally reproducible pharmacological activity of the E-domain sequence. The broader review literature (Matheny et al. 2010, Endocrinology) noted that no stable endogenous protein corresponding exactly to the synthetic 24-amino acid MGF E-peptide had been definitively identified and isolated from in vivo biological fluids at the time of that review — though the indirect evidence for MGF E-domain activity remains substantial.
A second important limitation: PEG-MGF specifically has limited published peer-reviewed pharmacokinetic and pharmacodynamic characterization as a distinct entity. Most mechanistic understanding of PEG-MGF is inferred from studies using non-pegylated synthetic MGF E-peptide, with the PEGylation assumed to extend half-life while preserving biological activity — a well-validated assumption for PEGylation in general, but one that has not been exhaustively characterized for MGF-specific E-domain biology.
No human clinical trials of PEG-MGF have been published. All in vivo evidence is from rodent or sheep animal models.
PEG-MGF vs IGF-1 LR3 — Key Distinctions for Research Context
PEG-MGF and IGF-1 LR3 are both IGF-1-system derived research compounds that promote muscle-related anabolic signaling, but they represent distinct biological mechanisms that are not interchangeable in research design.
IGF-1 LR3 is a modified form of mature IGF-1 — retaining the full IGF-1 receptor-binding domain and activating IGF-1R directly. Its primary signaling is through PI3K/Akt (driving protein synthesis, anti-apoptosis, and differentiation) and is systemic — circulating throughout the body and acting on all tissues expressing IGF-1R.
PEG-MGF is based on the MGF E-domain — the sequence unique to the IGF-1Ec splice variant that is distinct from the mature IGF-1 receptor-binding domain. Its biological activity involves satellite cell activation and a predominantly ERK-mediated signaling pattern, with apparent localization to the site of mechanical stress or injury. It does not activate IGF-1R with the potency of mature IGF-1 at pharmacologically relevant synthetic peptide concentrations.
In the physiological repair cascade, MGF acts first to amplify the satellite cell pool, with IGF-1Ea following to drive differentiation. Research designs exploring the full muscle repair process may benefit from understanding this temporal distinction when designing protocols involving both compound classes.
Current Research Status
PEG-MGF is not FDA-approved for any therapeutic indication and is classified as a WADA-prohibited substance under S2. Research interest is active in muscle wasting disorders (sarcopenia, muscular dystrophy, ALS), post-injury muscle repair, cardiac ischemia protection, neuroprotection (including Parkinson’s disease models), and aging biology. The full clinical translation of MGF-based therapeutics awaits resolution of the mechanistic controversies around E-domain independent activity and in vivo production of the autonomous E-peptide, as well as completion of IND-enabling preclinical toxicology and efficacy studies. No human clinical trials have been published.
Reconstitution Note
PEG-MGF is supplied as a lyophilized powder. Bacteriostatic water is the standard reconstitution solvent. The PEG conjugation increases solubility relative to the non-pegylated peptide. Protect from light. Gentle mixing is preferred — avoid vigorous shaking, which can disturb the PEG-peptide conjugate. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light. Avoid vigorous agitation. Avoid repeated freeze-thaw cycles. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of degradation.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the PEG-MGF product page: https://roguecompounds.com/product/peg-mgf/